Gilead Sciences Inc (GILD) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition o...
Gilead Sciences Inc (GILD) currently trades at a P/E ratio of 17.19 (historical range: 9.89–1169.44, median: 19.23), placing it at the 22th percentile — below its historical average, P/S ratio of 6.36 (range: 2.65–6.72, 99th percentile — expensive relative to its history), EV/EBITDA of 19.56 (range: 8.02–211.75, 65th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Gilead Sciences Inc's P/E ratio has expanded by 1230% over the observed period (from an average of 18.9 to 251.1).
Gilead Sciences Inc trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 17.19 | 19.23 | 22th | below its historical average |
| P/S Ratio | 6.36 | 3.73 | 99th | expensive relative to its history |
| EV/EBITDA | 19.56 | 17.60 | 65th | above its historical average |
| FCF Yield | 6.68% | 8.25% | 20th | expensive relative to its history |
Gilead Sciences Inc (GILD) Valuation & P/E History
Gilead Sciences Inc (GILD) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry currently trading at $156.84 with a market capitalization of $194.5 billion. This page provides historical valuation analysis for GILD based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 17.19 is below the historical median of 19.23, placing GILD at the 22th percentile of its valuation range. The P/S ratio of 6.36 compares to a median of 3.73.
GILD Valuation Metrics & Historical Range
The valuation table above shows Gilead Sciences Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether GILD is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests GILD is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Gilead Sciences Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is GILD Overvalued or Undervalued?
Gilead Sciences Inc trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 62 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive GILD is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full GILD analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.GILD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.